Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial

BACKGROUND: Neoadjuvant therapy has several potential advantages over upfront surgery in patients with localized pancreatic cancer; more patients receive systemic treatment, fewer patients undergo futile surgery, and R0 resection rates are higher, thereby possibly improving overall survival (OS). Tw...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Janssen, Q. P., van Dam, J. L., Bonsing, B. A., Bos, H., Bosscha, K. P., Coene, P. P. L. O., van Eijck, C. H. J., de Hingh, I. H. J. T., Karsten, T. M., van der Kolk, M. B., Patijn, G. A., Liem, M. S. L., van Santvoort, H. C., Loosveld, O. J. L., de Vos-Geelen, J., Zonderhuis, B. M., Homs, M. Y. V., van Tienhoven, G., Besselink, M. G., Wilmink, J. W., Groot Koerkamp, B.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2021
Matèries:
Study Protocol
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7989075/
https://ncbi.nlm.nih.gov/pubmed/33757440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-021-08031-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars